about
Therapeutic antibodies, vaccines and antibodyomesPreclinical development of monoclonal antibodies: considerations for the use of non-human primatesPhysics of pure and non-pure positron emitters for PET: a review and a discussionFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsCells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface displayAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsIntroducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody propertiesLow level sequence variant analysis of recombinant proteins: an optimized approachCharacterizing monoclonal antibody structure by carbodiimide/GEE footprintingSeizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China.Antibody-based imaging of HER-2: moving into the clinic.Noninvasive and targeted drug delivery to the brain using focused ultrasound.Engineering bispecificity into a single albumin-binding domain.A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.Antibodies to watch in 2010Trends in risks associated with new drug development: success rates for investigational drugs.Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum.Humanization and characterization of an anti-ricin neutralization monoclonal antibodyRapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Unraveling the autoimmune translational research process layer by layer.Computer-aided antibody design.Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting.In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa.Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm.Probabilities of success for antibody therapeutics.Antibody fragments: hope and hype.Structural and mechanistic insight into how antibodies inhibit serine proteases.Therapeutic monoclonal antibody concentration monitoring: free or total?Macromolecules as taxane delivery systems.Nanobody; an old concept and new vehicle for immunotargeting.Alternative affinity tools: more attractive than antibodies?The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.Intranasal delivery of therapeutic proteins for neurological diseases.Continuing pursuit for ideal systemic anticancer radiotherapeutics.Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects.State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.History of protein-protein interactions: from egg-white to complex networks.
P2860
Q24599662-1F444D83-20F2-4EAB-A102-2DB45E2EFA73Q24655266-8146E34B-58C7-4E40-9F42-901B51996F60Q26748495-D8A4CF42-4191-426E-B7D6-44EE256C4C94Q26822421-468A3B0E-0F10-46F9-8A2D-71B091AD6E99Q26849777-854A45B9-02AE-4EAA-AA26-1C7B3B510D09Q28270261-C99B2930-2DAB-4000-B07E-FAC543587017Q28272997-484CD0C0-CFBF-45EE-9C4A-3107A7BA84A8Q28727418-D6A118E1-D212-4736-855D-B483C6E6D703Q30369478-C2DE8620-3CAC-48AD-9483-06D45E2E15A3Q30387074-4A19B799-4D41-404A-BFA7-DA7B5BE3ECE4Q30423880-9C207208-1A10-4103-A537-C9BB3D36472DQ30439968-6CEF0AB2-6C9F-4F83-B59A-FECBFFDDDBC2Q31032588-B84D47A7-A609-4778-B6CF-DBE6E74BC20CQ33634142-49F995D6-CD28-450E-94EA-4033A5E0A9ACQ33688243-A8D1AE2A-E713-44F9-AAFA-9F29A154E728Q34096792-E12BE459-C444-444E-9DB5-07CD3A6ABE3AQ34223925-2421705C-929D-49B0-B4FA-1506607EEC40Q34438229-D6F3D091-FD6F-411F-9A27-6C8E30A98908Q35232337-7F628D87-B8B1-4402-89FB-7E48AEC6D30CQ35459059-621C5A97-DB99-4E4D-9A8E-C52575D3B497Q36116913-B12840EC-81A1-4DAB-9452-4F5FB9A5A088Q36254449-C7298CEF-6EB7-412A-99BA-8B7543BCCB98Q36588729-58AC54C3-E292-4814-BC10-77BC4904746EQ36613653-CC2DAE47-5181-48E1-9703-6DE5A2BD41E4Q36951905-5D7F7D48-F4B4-468A-86A1-C877760C28F0Q37031461-B69826D3-9772-4D9B-9DDA-98CAB10B5234Q37304479-A5440B8B-1F73-4441-8521-9BEF3CFDB071Q37679663-88462316-3811-4A9C-9E21-3A985BBBC1CDQ37779571-58ABDC31-9614-4875-A5FF-FABE522BA801Q37810218-F1EBECC0-E933-4F2C-AD35-80A477D3EA25Q37818236-6F577346-84B7-4E56-8ED4-5819AD1EFFFFQ37829737-E2366B6F-0EDB-4B4A-907C-CB20C357106BQ37869534-EE969E29-CCD7-4FCE-92EF-69EEA5B71E5EQ37869905-97CFF4DC-89E5-49FB-BBA8-A5E63730E98AQ37880893-E5F9DAA4-657F-4D7C-873D-573FA4187A8DQ37946750-5015751B-29B6-4C8C-BB84-7E96D8DC453AQ37947551-278380C6-CF8A-4DD6-8387-EFBA4E314B5EQ37955034-F7A58581-8A03-446F-9916-5BDAA6F0F56AQ38013999-9FA798B6-2876-4697-AECD-3747E9B97683Q38019869-7924E797-126A-45B9-94E1-CFDAFE2EA20E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monoclonal antibodies as innovative therapeutics.
@en
Monoclonal antibodies as innovative therapeutics.
@nl
type
label
Monoclonal antibodies as innovative therapeutics.
@en
Monoclonal antibodies as innovative therapeutics.
@nl
prefLabel
Monoclonal antibodies as innovative therapeutics.
@en
Monoclonal antibodies as innovative therapeutics.
@nl
P1476
Monoclonal antibodies as innovative therapeutics.
@en
P2093
Janice M Reichert
P304
P356
10.2174/138920108786786358
P577
2008-12-01T00:00:00Z